tiprankstipranks
Ascom Holding AG (CH:ASCN)
:ASCN
Want to see CH:ASCN full AI Analyst Report?

Ascom Holding AG (ASCN) AI Stock Analysis

2 Followers

Top Page

CH:ASCN

Ascom Holding AG

(ASCN)

Select Model
Select Model
Select Model
Outperform 78 (OpenAI - 5.2)
Rating:78Outperform
Price Target:
CHF6.50
▲(4.50% Upside)
Action:UpgradedDate:03/12/26
The score is driven primarily by improving financial performance and a low-risk balance sheet (no reported debt), supported by a positive technical trend and an undemanding valuation (P/E 8.953). The main offset is modest/uneven revenue growth and historical cash-flow volatility.
Positive Factors
Improved Cash Generation
Strong operating cash flow and free cash flow in 2025, with FCF roughly equal to net income, point to higher quality earnings and the ability to self-fund maintenance, support contracts, and modest strategic initiatives in mission‑critical healthcare environments.
Negative Factors
Stagnant Revenue
Revenue has been modest and uneven across 2021–2025, limiting the company's ability to scale fixed-costs and achieve sustained operating leverage. Persistent top-line stagnation forces reliance on margin improvement or service mix changes to drive long-term EPS growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Cash Generation
Strong operating cash flow and free cash flow in 2025, with FCF roughly equal to net income, point to higher quality earnings and the ability to self-fund maintenance, support contracts, and modest strategic initiatives in mission‑critical healthcare environments.
Read all positive factors

Ascom Holding AG (ASCN) vs. iShares MSCI Switzerland ETF (EWL)

Ascom Holding AG Business Overview & Revenue Model

Company Description
Ascom Holding AG, together with its subsidiaries, provides healthcare ICT and mobile workflow solutions worldwide. The company offers nurse call and monitoring systems, including teleCARE IP that provides nurse call, alerts, messaging, monitoring,...
How the Company Makes Money
Ascom makes money by selling and supporting communication and workflow technology solutions. Its revenue typically comes from (1) software: licensing or subscriptions for applications that manage alarms/events, messaging, and workflow orchestratio...

Ascom Holding AG Financial Statement Overview

Summary
Profitability rebounded in 2025 (net income 15.1m; net margin ~5.2% vs ~1.3% in 2024) and the balance sheet is conservative with no reported debt in 2023–2025. Free cash flow improved in 2025 (31.6m), but revenue growth has been modest/uneven and cash flow was volatile historically (negative FCF in 2021–2022).
Income Statement
71
Positive
Balance Sheet
86
Very Positive
Cash Flow
67
Positive
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue292.10M286.70M297.30M297.40M291.50M
Gross Profit140.70M133.30M141.40M135.40M135.60M
EBITDA34.20M13.80M31.30M25.90M28.80M
Net Income15.10M3.70M17.40M11.00M13.50M
Balance Sheet
Total Assets199.60M189.90M197.20M201.80M194.70M
Cash, Cash Equivalents and Short-Term Investments29.60M18.60M24.70M26.60M29.50M
Total Debt0.000.000.0010.00M0.00
Total Liabilities119.70M115.50M118.50M128.40M114.70M
Stockholders Equity79.90M74.40M78.70M73.40M80.00M
Cash Flow
Free Cash Flow31.60M15.60M16.30M-3.20M-100.00K
Operating Cash Flow32.60M20.00M32.50M10.20M11.60M
Investing Cash Flow-10.80M-15.50M-16.20M-14.00M5.20M
Financing Cash Flow-10.40M-10.80M-17.20M2.20M-19.00M

Ascom Holding AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
CHF189.68M8.954.02%2.75%1.88%314.17%
56
Neutral
CHF351.97M71.614.54%-7.42%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
CHF1.02B131.1319.76%150.73%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CH:ASCN
Ascom Holding AG
5.26
2.24
74.06%
MEDGF
Medacta Group SA
185.31
25.69
16.09%
SGFEF
Siegfried Holding AG
100.00
-9.36
-8.56%
DE:283
IVF HARTMANN Holding AG
141.00
8.76
6.62%
CH:MEDX
medmix AG
8.53
-1.60
-15.77%
CH:MED
Medartis Holding AG
73.50
-1.00
-1.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 12, 2026